The Bruton’s tyrosine kinase (BTK) inhibitor acalabrutinib demonstrates potent on-target effects and efficacy in two mouse models of chronic lymphocytic leukemia

PURPOSE: Acalabrutinib (ACP-196) is a novel, potent, and highly selective BTK inhibitor, which binds covalently to Cys481 in the ATP-binding pocket of BTK. We sought to evaluate the anti-tumor effects of acalabrutinib treatment in two established mouse models of chronic lymphocytic leukemia (CLL). E...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Clin Cancer Res
Main Authors: Herman, Sarah E. M., Montraveta, Arnau, Niemann, Carsten U., Mora-Jensen, Helena, Gulrajani, Michael, Krantz, Fanny, Mantel, Rose, Smith, Lisa L., McClanahan, Fabienne, Harrington, Bonnie K., Colomer, Dolors, Covey, Todd, Byrd, John C., Izumi, Raquel, Kaptein, Allard, Ulrich, Roger, Johnson, Amy J., Lannutti, Brian J., Wiestner, Adrian, Woyach, Jennifer A.
Formato: Artigo
Idioma:Inglês
Publicado em: 2016
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5548968/
https://ncbi.nlm.nih.gov/pubmed/27903679
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-16-0463
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados